

Media Release

DKSH and Schweitzer Health Biotech Co. Ltd Join Forces to Foster Gastrointestinal Well-being in Hong Kong

Strong Alliance formed as DKSH and Schweitzer Health Biotech Co. Ltd officially announce their new partnership at the “Asia Summit on Global Health”, witnessed by healthcare industry leaders, to drive gastrointestinal well-being in Hong Kong.

Hong Kong, May 22, 2024 – DKSH Business Unit Healthcare Hong Kong, a leading provider of Market Expansion Services, is pleased to announce its new partnership with Schweitzer Health Biotech Co. Ltd (SHBC) aimed at promoting gastrointestinal health and well-being in Hong Kong. The contract signing ceremony took place at the prestigious “Asia Summit on Global Health”, jointly organized by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council, held at the Hong Kong Convention and Exhibition Center.

As a trusted partner, DKSH will provide comprehensive agency services for SHBC’s flagship product, “Weider Probiotics Immune & Digestive Support 30’s”, in Hong Kong. Leveraging their extensive distribution network, industry knowledge, and comprehensive range of services, DKSH aims to effectively promote and distribute this exceptional product, thereby supporting the goal of fostering gastrointestinal health and well-being in the region.

Recognized as Asia’s premier event on health innovation and investment, the “Asia Summit on Global Health” (ASGH) brings together policymakers, healthcare experts, academia, business leaders, and industry players. With over 2,500 participants from 40 countries and regions, ASGH 2024 featured thematic sessions focusing on the latest trends in various medical sectors. As one of the “Healthcare Champions” of ASGH 2024, DKSH conducted the contract signing ceremony with SHBC, highlighting their prominent positions in both Hong Kong and Taiwan and fostering international exchange and collaborations.

Expressing enthusiasm about the partnership, Mr. James Chen, Chairman of Schweitzer Health Biotech Co. Ltd., stated: “We are thrilled by this partnership with DKSH Business Unit Healthcare Hong Kong, a reliable market expansion service provider deeply specialized in the healthcare markets of Hong Kong and Macau. This collaboration allows us to convey our sincere gratitude to Hong Kong consumers with the brand-new enhanced formula for their continued demand for Weider Probiotics. As local awareness of gastrointestinal health continues to rise, we are optimistic about the prospects that lie ahead.”

Mr. Fong Wai Ting, Head of Management and Vice President, DKSH Healthcare Hong Kong & Macau, stated: “We are delighted to form our first partnership with Schweitzer Health Biotech Co. Ltd. This strategic alliance is a major milestone for us, as we strive to offer healthcare solutions that empower individuals to enjoy healthier lives. With a keen awareness of the growing demand for gastrointestinal health, we foresee abundant opportunities on the horizon. Our joint endeavors will contribute to a brighter future in consumer health, fostering accessibility and enhancing healthcare for all.”

About DKSH

DKSH’s purpose is to enrich people’s lives. For almost 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 29,040 specialists, generating net sales of CHF 11.1 billion in 2023. DKSH Business Unit Healthcare

distributes pharmaceuticals, consumer health, and over-the-counter products as well as medical devices. With around 8,140 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2023. www.dksh.com/hec

About Schweitzer Health Biotech Co. Ltd

Schweitzer Health Biotech Company Ltd. (SHBC) is a forward-thinking biotech company specializing in precision probiotic products aimed at enhancing human gastrointestinal health and overall well-being. SHBC's premier offering, Weider Probiotics, a renowned sports and health brand boasting 85 years of legacy, has sold over 800 million packets in Taiwan and Japan. With a consistent No. 1 status in Taiwan's probiotic market for three consecutive years, SHBC remains steadfast in its mission to provide the world with "safe, effective, and easily supplemented" nutritional supplements.

For further information, please contact:

DKSH Hong Kong
Sandy Sum
Manager, Marketing & Communications
Tel: +852 2895 9610
sandy.sum@dksh.com